Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #77936 on Canopy Growth Corp (WEED)
mkendra
06/10/18 1:59 PM
#77938 RE: Dbrown13 #77936
JohnCM
06/10/18 2:14 PM
#77939 RE: Dbrown13 #77936
Imo the only thing GW has is patents.
Manufacturing We are responsible for the manufacture and supply of our products for clinical trial and commercial purposes. We operate under GMP manufacturing licenses issued by the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom and our facilities have been audited by the MHRA on a regular basis. We have personnel with extensive experience in production of botanical raw material, pharmaceutical production, quality control, quality assurance and supply chain Our research to date has focused on the following plant-based cannabinoids: CBD (Cannabidiol) CBN (Cannabinol) CBDV (Cannabidivarin) CBNV (Cannabinovarin) CBDA (Cannabidiol—Acid) D8-THC (Delta-8 Tetrahydrocannabinol) CBDVA (Cannabidivarin—Acid) THC (Delta-9 Tetrahydrocannabinol) CBC (Cannabichromene) THCA (Tetrahydrocannabinol—Acid) CBG (Cannabigerol) THCV (Tetrahydrocannabivarin) CBGA (Cannabigerol—Acid) THCVA (Tetrahydrocannabivarin—Acid) CBGV (Cannabigerovarin) Bayer HealthCare AG. In 2003, we entered into an agreement with Bayer whereby we granted Bayer an exclusive license to market Sativex in the United Kingdom. This agreement was amended later in 2003 to include Canada. Under the agreement, we are the marketing authorization holder for Sativex in the United Kingdom and Canada. In addition, we are responsible for commercial product supply to Bayer. The financial terms of the agreement included an upfront fee of £5.0 million. In addition, milestone payments are payable on the successful completion of certain development activities, as well as on regulatory approvals and the achievement of specified sales targets. Since its initial execution in 2003, the agreement has been the subject of various amendments, one of which included the provision of new milestone payments. In total, we have received £19.8 million in milestone payments from Bayer. We have the potential to receive a further £9.0 million in milestone payments in the event that the relevant milestones are achieved, all of which are related to future regulatory approvals. We also receive revenue from supply of Sativex, equating to a percentage in the mid-thirties to forty of Bayer’s in-market net sales revenue.
06/10/18 2:40 PM
#77946 RE: Dbrown13 #77936